Table 3.

Unit costs utilized in the analysis

Cost driver	Expense	Cost (€)	Reference
Drug acquisition	Cladribine 10 mg, 1 tbl	2433.69	FMT 06/19 [34]
	Cladribine 10 mg, 4 tbl	9624.82	FMT 06/19 [34]
	Cladribine 10 mg, 6 tbl	14,418.91	FMT 06/19 [34]
	Fingolimod 0.5 mg 7tbl	427.62	FMT 06/19 [34]
	Fingolimod 0.5 mg 28tbl	1612.99	FMT 06/19 [34]
	Natalizumab 300 mg	2250.00	FMT 06/19 [34]
Drug administration	Natalizumab NaCl for infusion	0.87	FMT 06/19 [34]
	Natalizumab infusion administratione	309.82	[38] indexed to 2018 valuea
Monitoring	Electrocardiogram (EKG), 6 hf	587.00	[30]
	Full blood count, FBC	4.60	[35]
	JC virus antibodies	70.00	[35]
	Latent infections	120.53	[35]
	Magnetic resonance imaging (MRI) of head and spinee	320.00	[30]
	Ophthalmologic examinatione	215.60	[36] indexed to 2018 valuea
	Transaminases, bilirubin	4.00	[35]
	Varicella zoster (VZ) antibodies	20.00	[35]
	VZ vaccinationd	203.68	[36] indexed to 2018 valuea/FMT 6/2019 [34]
	Test takingd	5.52	[37] indexed to 2018 valuea
Adverse event	Abnormal laboratory findings related to liver functiond	96.26b	[36] indexed to 2018 valuea, VSSHP [35]
	Lymphopeniad	226.83c	[36] indexed to 2018 valuea, [35]
Travelling	Primary care	7.40	[37] indexed to 2018 valuea
	Secondary care	37.80	[37] indexed to 2018 valuea
Productivity loss	Primary care (1/4 day)	64.24	[42] indexed to 2018 valuea
	Secondary care (half a day)	128.48	[42] indexed to 2018 valuea
	Full day	256.96	[42] indexed to 2018 valuea

FMT Finnish Medicines Tariff

^aOfficial Statistics of Finland [41]

^bBlood test, specialist paper consultation, specialist telephone consultation, 5% of patients an additional specialist visit and upper stomach ultrasound

^cLymphocytes differential count, specialist paper consultation, specialist telephone consultation

^dProductivity loss and travelling cost for this procedure estimated to be ¼ day

^eProductivity loss and travelling cost for this procedure estimated to be ½ day

^fProductivity loss and travelling cost for this procedure estimated to be full day